Skip to main content
SpringerLink
Log in

Botulinum toxin A cost effective for OAB in US

  • Meeting report
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. 2014 US dollars

Reference

  • Hepp Z, et al. Cost Effectiveness of Onabotulinumtoxina Versus PTNS and SNS for the Treatment of Overactive Bladder from the US Payer Perspective. 21st Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research : (plus poster) abstr. PUK11, 21 May 2016. Available from: URL: http://www.ispor.org/research_study_digest/list.asp?qs=44793

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Botulinum toxin A cost effective for OAB in US. PharmacoEcon Outcomes News 755, 13 (2016). https://doi.org/10.1007/s40274-016-3120-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-016-3120-3

Search

Navigation